These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31139472)

  • 1. Immunohistochemical Analysis of BRAF (V600E) Mutation and P16 Expression in Malignant Melanoma in Lagos, Nigeria: A 10-Year Retrospective Study.
    Obadofin O; Badmos K; Orsi N; Bipin M; Rotimi O; Banjo A
    J Skin Cancer; 2019; 2019():1628247. PubMed ID: 31139472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant Melanoma in Lagos, Nigeria: Elucidating Histopathologic Prognostic Factors.
    Obadofin OO; Badmos KB; Omoseebi OO; Banjo AAF
    West Afr J Med; 2022 Jun; 39(6):623-627. PubMed ID: 35752963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.
    Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF
    Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population.
    Mackiewicz-Wysocka M; Czerwińska P; Filas V; Bogajewska E; Kubicka A; Przybyła A; Dondajewska E; Kolenda T; Marszałek A; Mackiewicz A
    Postepy Dermatol Alergol; 2017 Oct; 34(5):490-498. PubMed ID: 29507566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathologic and Molecular Features of Cutaneous Melanoma in a Moroccan Population.
    Tahiri Elousrouti L; Hammas N; Fadlallah I; Elberdai S; Amaadour I; Elloudi S; Elmernissi FZ; Elidrissi M; Hassani W; Alami B; Chbani L
    Cureus; 2023 Jul; 15(7):e42691. PubMed ID: 37649946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
    Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
    Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical Investigation of Mutant BRAF V600E in Common Pigmented Skin Neoplasms, Study on a Sample of Iranian Patients.
    Ghasemi M; Vahedi Larijani L; Emadian O; Yazdani J; Sajadianfar A; Abediankenari S
    Iran J Pathol; 2019; 14(1):8-16. PubMed ID: 31531096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of BRAF
    Abd Elmageed ZY; Moore RF; Tsumagari K; Lee MM; Sholl AB; Friedlander P; Al-Qurayshi Z; Hassan M; Wang AR; Boulares HA; Kandil E
    J Am Coll Surg; 2018 Apr; 226(4):526-537. PubMed ID: 29369798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular features of metanephric adenoma and their values in differential diagnosis].
    Wang X; Shi SS; Yang WR; Ye SB; Li R; Ma HH; Zhang RS; Lu ZF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):38-42. PubMed ID: 28072975
    [No Abstract]   [Full Text] [Related]  

  • 10. The \textit{BRAF} V600E mutation in single- institution study of Russian melanoma patients.
    Lyubchenko L; Emelyanova M; Shamanin V; Demidov L; Zasedatelev A; Nasedkina T
    Cancer Biomark; 2016; 16(1):153-60. PubMed ID: 26600396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
    Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.
    Thiel A; Moza M; Kytölä S; Orpana A; Jahkola T; Hernberg M; Virolainen S; Ristimäki A
    Hum Pathol; 2015 Feb; 46(2):169-75. PubMed ID: 25442222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic findings and BRAF mutation in cutaneous melanoma in young adults.
    Estrozi B; Machado J; Rodriguez R; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):57-64. PubMed ID: 24471189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
    Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
    JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.
    Koelsche C; Sahm F; Wöhrer A; Jeibmann A; Schittenhelm J; Kohlhof P; Preusser M; Romeike B; Dohmen-Scheufler H; Hartmann C; Mittelbronn M; Becker A; von Deimling A; Capper D
    Brain Pathol; 2014 Apr; 24(3):221-9. PubMed ID: 24345274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
    Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.